Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Breast Neoplasms 412Carcinoma, Non-Small-Cell Lung 359Neoplasms 327Prostatic Neoplasms 267Colorectal Neoplasms 261Multiple Myeloma 204Lung Neoplasms 195Neoplasm Metastasis 183Leukemia, Myeloid, Acute 158Ovarian Neoplasms 151Pancreatic Neoplasms 143Squamous Cell Carcinoma of Head and Neck 134Melanoma 125Recurrence 99Carcinoma, Renal Cell 99Glioblastoma 96Endometrial Neoplasms 96Stomach Neoplasms 93Precursor Cell Lymphoblastic Leukemia-Lymphoma 92Lymphoma, Non-Hodgkin 92Carcinoma, Hepatocellular 92Head and Neck Neoplasms 91Lymphoma 88Triple Negative Breast Neoplasms 84Uterine Cervical Neoplasms 80Brain Neoplasms 79Sarcoma 78Glioma 75Urinary Bladder Neoplasms 74Lymphoma, Large B-Cell, Diffuse 74

Interventions

Paroxetine 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lethal Congenital Contracture Syndrome 2 × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡